MabThera Articles
Roche aims for expansion in Russia; Pharmsynthez production plans
20 February 2013
New Zealand's PHARMAC decisions on Roche products
11 October 2012
UK NICE says Novartis MS drug Gilenya not cost effective, but backs extended use of Roche’s MabThera
1 December 2011
Stada Arz and Richter link up to develop and market two biosimilars: rituximab and trastuzumab
1 September 2011
Rheumatologists’ uptake of Benlysta will not lead to decline in patient share for immunosuppressant/cytotoxics or for Rituxan through 2013
24 February 2011
Sandoz moves forward with development of biosimilar rituximab, Roche’s blockbuster RA drug
11 January 2011
Maintenance for follicular non-Hodgkin's lymphoma with Roche’s MabThera backed by UK’s NICE; positive new data presented at ASH
6 December 2010
GlaxoSmithKline/HGS's Benlysta will push SLE drug market to more than $1.6 billion in 2019
10 August 2010
Product marketing briefs from Merck & Co, Merck Serono, GW/Almirall, AstraZeneca and Roche
28 July 2010
Showing 1-15 of 15 articles
- 1
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Elan puts up formal "for sale" notice
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
